Get the Stockscreener App
6.84
0.59%
0.04
After Hours:
6.84
Aura Biosciences Inc stock is traded at $6.84, with a volume of 103.65K.
It is up +0.59% in the last 24 hours and up +6.87% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$6.80
Open:
$6.83
24h Volume:
103.65K
Relative Volume:
0.49
Market Cap:
$343.84M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-3.5625
EPS:
-1.92
Net Cash Flow:
$-64.56M
1W Performance:
+3.48%
1M Performance:
+6.87%
6M Performance:
-11.51%
1Y Performance:
-17.59%
1-Day Range:
$6.65
$6.96
1-Week Range:
$6.30
$7.02
52-Week Range:
$4.345
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
6.84 | 424.11M | 0 | -76.41M | -64.56M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
638.90 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Stock (AURA) Latest News
Combining price and volume data for Aura Biosciences Inc.Portfolio Allocation Strategy for Stability - Newser
What MACD and RSI say about Aura Biosciences Inc.Free Real Profit Trade Plan Suggestions - Newser
Aura Biosciences Inc.’s volatility index tracking explainedMarket Liquidity and Price Flow Analysis - Newser
Key resistance and support levels for Aura Biosciences Inc.Weekly High Conviction Trade Setup Analysis - Newser
Order flow analysis tools used on Aura Biosciences Inc.Buy and Hold Return Summary with Charts - Newser
Market reaction to Aura Biosciences Inc.’s recent newsProfit Target Planning with Exit Confidence - Newser
What makes Aura Biosciences Inc. stock price move sharplyFree Buy Low Sell High Stock Watch - Newser
Can Aura Biosciences Inc. rally from current levelsBuy Signal System Based on Price Action - Newser
Analyzing drawdowns of Aura Biosciences Inc. with statistical toolsFree Access to Real-Time Trade Insights - Newser
Understanding Aura Biosciences Inc.’s price movementSmart Chart Forecasting with AI Algorithms - Newser
Aura Biosciences (AURA) Expected to Announce Quarterly Earnings on Thursday - Defense World
Regression analysis insights on Aura Biosciences Inc. performanceFree Fast Gaining Stock Screener Report - Newser
Why Aura Biosciences Inc. stock attracts strong analyst attentionSmart Trend Analysis With Buy Point Cues - Newser
Aura Biosciences shares fall 1.78% intraday as Wall Street recovers from Friday's selloff. - AInvest
What are Aura Biosciences Inc. company’s key revenue driversFree Trading Psychology Coaching - Jammu Links News
What drives Aura Biosciences Inc. stock priceGet daily expert analysis for smarter investing - Jammu Links News
What analysts say about Aura Biosciences Inc. stockMaximize gains with strategic stock entries - Jammu Links News
What institutional investors are buying Aura Biosciences Inc. stockCapitalize on emerging industry trends - Jammu Links News
Why is Aura Biosciences Inc. stock attracting strong analyst attentionInvest confidently with data-driven strategies - Jammu Links News
How strong is Aura Biosciences Inc. company’s balance sheetFree Predictions - Jammu Links News
What is Aura Biosciences Inc. company’s growth strategyRobust investment performance - Jammu Links News
Is Aura Biosciences Inc. a candidate for recovery playRisk Shielded Trade Watch with Analysis - Newser
Aura Biosciences Inc. Testing Reversal Zone on Weekly ChartBuy Alerts With Low Risk Confirmation Noted - metal.it
How many analysts rate Aura Biosciences Inc. as a “Buy”Low Risk Recommendation With High Returns - jammulinksnews.com
New Product Launches: Will They Boost Aura Biosciences Inc. Stock in 2025Weekly Price Target Forecast and Alerts - Newser
How does Aura Biosciences Inc. generate profit in a changing economyExpert Picks Report For Fast Growth - Jammu Links News
Sectors Driving Future Growth for Aura Biosciences Inc. StockGrowth Watchlist for Long Term Positioning - Newser
Short Term Charts Align With Long Term Uptrend in Aura Biosciences Inc.AI Based High Gain Watchlist Scanner Shared - metal.it
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aura Biosciences Inc Stock (AURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Johnson David Michael | Director |
May 16 '25 |
Buy |
4.90 |
20,000 |
98,000 |
166,167 |
| Gibney Anthony S | See Remarks |
May 16 '25 |
Buy |
4.90 |
50,000 |
245,000 |
58,452 |
| Gibney Anthony S | See Remarks |
May 16 '25 |
Sale |
5.15 |
1,519 |
7,823 |
56,933 |
3.70%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):